The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib

by Medina, Theresa M, Lewis, Karl D
Published 2016

Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control

by Stinauer, Michelle A, Kavanagh, Brian D, Schefter, Tracey E, Gonzalez, Rene, Flaig, Thomas, Lewis, Karl, Robinson, William, Chidel, Mark, Glode, Michael, Raben, David
Published 2011

ABT-737 synergizes with Bortezomib to kill melanoma cells

by Reuland, Steven N., Goldstein, Nathaniel B., Partyka, Katie A., Smith, Shilo, Luo, Yuchun, Fujita, Mayumi, Gonzalez, Rene, Lewis, Karl, Norris, David A., Shellman, Yiqun G.
Published 2011

Side Population Cells from Human Melanoma Tumors Reveal Diverse Mechanisms for Chemoresistance

by Luo, Yuchun, Ellis, Lixia Z, Dallaglio, Katiuscia, Takeda, Moe, Robinson, William A, Robinson, Steven, Liu, Weimin, Lewis, Karl D, McCarter, Martin D, Gonzalez, Rene, Norris, David A, Roop, Dennis R, Spritz, Richard A, Ahn, Natalie G, Fujita, Mayumi
Published 2012

Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion

by Ribas, Antoni, Chesney, Jason A, Gordon, Michael S, Abernethy, Amy P, Logan, Theodore F, Lawson, David H, Chmielowksi, Bartosz, Glaspy, John A, Lewis, Karl, Huang, Bo, Wang, Erjian, Hsyu, Poe-Hirr, Gomez-Navarro, Jesus, Gerhardt, Diana, Marshall, Margaret A, Gonzalez, Rene
Published 2012

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

by Lam, Elaine T., Wong, Michael K. K., Agarwal, Neeraj, Redman, Bruce G., Logan, Theodore, Gao, Dexiang, Flaig, Thomas W., Lewis, Karl, Poust, Jamie, Monk, Paul, Jarkowski, Anthony, Sendilnathan, Arun, Bolden, Marcus, Kuzel, Timothy M., Olencki, Thomas
Published 2014